LONDON (AP) -- GlaxoSmithKline says its sales of drugs and vaccines in China tumbled in the third quarter as it was hit by bribery investigations there.

Worldwide sales, it says, were flat as growth in the U.S. and Europe helped offset China's 61% drop. Total revenue rose 1% to 6.51 billion pounds ($10.5 billion).

The company was hit by allegations by the Chinese government that four of its employees paid bribes to doctors and hospitals to encourage them to prescribe medications.

Chief Executive Andrew Witty said Wednesday that the decline in China was disappointing but it was too early to judge the long-term impact of the probe.

The company said it expected earnings per share to grow between 3% and 4% this year.


The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.